Skip to content

Efficacy evaluation of probiotics (Bifidobacterium bifidum BGN4) in the liver enzyme and systemic inflammation associated with body fat

Efficacy evaluation of probiotics (Bifidobacterium bifidum BGN4) in the liver enzyme and systemic inflammation associated with body fat

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CRIS
Registry ID
KCT0010817
Enrollment
60
Registered
2025-07-28
Start date
2024-04-01
Completion date
Unknown
Last updated
2025-08-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Others(Bifidobacterium bifidum BGN4 Probiotics) : Based on the inclusion and exclusion criteria, a total of 60 eligible participants were selected and randomly assigned to one of two groups (n = 30 pe

Sponsors

Sookmyung Women's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: -Adults aged 19 to 64 years -Healthy adult men with a body fat percentage =20% and healthy adult women with a body fat percentage =28%

Exclusion criteria

Exclusion criteria: - Individuals with severe or chronic diseases such as malignant tumors, hypertension, diabetes, inflammatory bowel disease, renal or cardiac dysfunction, severe neurological disorders, psychiatric disorders, asthma, chronic obstructive pulmonary disease (COPD), or thyroid dysfunction (hyperthyroidism or hypothyroidism) - Individuals with liver disease, a history of liver-related conditions, or liver surgery - Individuals taking medications or supplements - Individuals who have taken any functional foods or medications intended to improve liver function or body fat composition within the past 4 weeks - Individuals who have taken prebiotics, probiotics, or synbiotics within the past 4 weeks - Individuals who have received antibiotic treatment within the past 3 months - Women who are pregnant, breastfeeding, or planning to become pregnant - Individuals with alcohol consumption >20 g/day for women (equivalent to ~2 glasses of beer or soju) or >30 g/day for men (~3 glasses of beer or soju) - Individuals with known allergies to probiotics or excipients - Individuals who have participated in a similar clinical trial within the past month

Design outcomes

Primary

MeasureTime frame
Serum hs-CRP

Secondary

MeasureTime frame
The relative abundance of Bifidobacterium bifidum BGN4;Serum fasting glucose;Serum fasting insulin;HOMA-IR;Serum Tumor Necrosis Factor a(TNFa);Serum zonulin;Serum Total antioxidant capacity(TAC);Serum Total cholesterol;Serum High-density lipoprotein(HDL) - cholesterol;Serum Low-density lipoprotein(LDL) - cholesterol;Serum Triglyceride(TG);Serum Aspartate aminotransferase(AST);Serum Alanine aminotransferase(ALT);Changes in fecal microbiota composition

Countries

Korea, Republic of

Contacts

Public ContactJuwon Choi

Sookmyung Women's Hospital

juwoni99@naver.com+82-2-710-9453

Outcome results

None listed

Source: CRIS (via WHO ICTRP) · Data processed: May 13, 2026